Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Change in Cash: 2010-2025

Historic Change in Cash for OptimizeRx (OPRX) over the last 16 years, with Q3 2025 value amounting to $2.9 million.

  • OptimizeRx's Change in Cash rose 15141.39% to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.3 million, marking a year-over-year increase of 15929.42%. This contributed to the annual value of -$472000.0 for FY2024, which is 8916.69% up from last year.
  • Latest data reveals that OptimizeRx reported Change in Cash of $2.9 million as of Q3 2025, which was up 15141.39% from $12000.0 recorded in Q2 2025.
  • Over the past 5 years, OptimizeRx's Change in Cash peaked at $71.8 million during Q1 2021, and registered a low of -$46.1 million during Q3 2022.
  • Over the past 5 years, OptimizeRx's median Change in Cash value was $115000.0 (recorded in 2023), while the average stood at $473784.7.
  • In the last 5 years, OptimizeRx's Change in Cash skyrocketed by 207006.82% in 2021 and then plummeted by 606858.1% in 2022.
  • Over the past 5 years, OptimizeRx's Change in Cash (Quarter) stood at -$374808.0 in 2021, then plummeted by 6068.58% to -$23.1 million in 2022, then soared by 117.0% to $3.9 million in 2023, then crashed by 169.87% to -$2.7 million in 2024, then soared by 206.85% to $2.9 million in 2025.
  • Its Change in Cash stands at $2.9 million for Q3 2025, versus $12000.0 for Q2 2025 and $3.2 million for Q1 2025.